Marketing-authorisation holder
La Jolla Limited
2 medicines in 2 countries, as authorisation holder.
Medicines
Every medicine in the registers under its name, current ones first.
2 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| GIAPREZA0.5mg base/ml (eq 0.5mg base/ml) | 2.5mg base/ml (eq 2.5mg base/ml) | 5mg base/2ml (eq 2.5mg base/ml) · Solution | Angiotensin ii | United States | Marketed | 2017 |
| Riquent | Abetimus | EU (EMA) | Refused |
Countries
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| European Union (EMA) | 1 | 0 | 1 | CompaniesAll medicines |
| United States | 1 | 1 | 0 | CompaniesAll medicines |
Top substances
The active substances in most of its medicines.
Names in the registers
How the registers spell it, normalised: legal forms, accents and capitals removed.
- la jolla
- la jolla pharma
Sources and licences
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
European Medicines Agency
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
U.S. Food and Drug Administration (Drugs@FDA, openFDA)
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.
At a glance
- Type
- Marketing-authorisation holder
- Medicines
- 2
- Countries
- 2
- Roles
- Authorisation holder